Xencor Inc
Xencor Inc (XNCR): 30 pipeline candidates · 2 upcoming catalysts · ~7 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
6.9 months
D/E 0.43 · 2% dilution
Lead: Approved
30 candidates
2 upcoming, next in ~4663d
0 buys · 11 sells (180d)
A transparent, data-derived signal for Xencor Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$970.5M
Cash
$14.4M
Quarterly Burn
$67.6M
Runway
6.9 mo
Revenue
$4.5M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (30 candidates)
| Drug | Phase |
|---|---|
| 5-FU | Phase 1 |
| AIMab7195 (XmAb7195) | Phase 1 |
| ASP2138 | Phase 1 |
| Efbalropendekin alfa (XmAb306 / RG6323) | Phase 1 |
| JNJ-1493 | Phase 1 |
| JNJ-9401 | Phase 1 |
| Leucovorin | Phase 1 |
| Monjuvi | Approved |
| Obexelimab | Phase 3 |
| OMS906 | Phase 2 |
Showing 10 of 30 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
201
Total value held
$972.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,035,918 | $157.2M |
| primecap management co/ca/ | 10,338,022 | $124.7M |
| bvf inc/il | 7,133,720 | $86.0M |
| rtw investments, lp | 6,777,461 | $81.7M |
| vanguard capital management llc | 6,203,294 | $74.8M |
| ra capital management, l.p. | 4,897,237 | $59.1M |
| state street corp | 4,352,036 | $52.5M |
| vanguard portfolio management llc | 3,500,342 | $42.2M |
| geode capital management, llc | 1,815,577 | $21.9M |
| morgan stanley | 1,558,290 | $18.8M |
Showing top 10 of 201 institutional holders of Xencor Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Xencor Inc's pipeline?
Xencor Inc (XNCR) has 30 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xencor Inc's lead drug candidate?
Xencor Inc's most advanced tracked candidate is 5-FU (Phase 1) for Pancreatic Ductal Adenocarcinoma.
What is Xencor Inc's next catalyst?
Xencor Inc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: KHAPZORY" — expected March 25, 2039.
What is Xencor Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xencor Inc has approximately 6.9 months of cash runway.
What is Xencor Inc's market capitalization?
Xencor Inc's market capitalization is approximately $970.5M.
Get the full picture on Xencor Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.